검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Levoleucovorin (Levoleucovorin) Seagen, a wholly owned subsidiary …·Gastroesophageal Junction 5%·t½ 5.1 h |
|---|---|
Overview Program | Levoleucovorin |
Overview Company | Seagen, a wholly owned subsidiary of Pfizer |
Overview Modality | ANTIBODY |
Overview Target | Gastroesophageal Junction |
Overview Indication | Colorectal Neoplasms |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | target for the treatment of cancer due to its involvement in base excision repair pathway |
MoA Biomarker | biomarkers and tumor samples for archival tissues were collected from all patients |
PK/PD Half-life | 5.1 h |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pharmacokinetic |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Vitamins, Vascular Health and Disease.. Vascular health relies on the proper function of endothelial cells, which regulate vascular tone, blood fluidity, and barrier integrity. Endothelial dysfunction, often aggravated by inadequate vitamin absorption, contributes to a spectrum of clinical disorders, including cardiovascular disease, cerebrovascular disease, peripheral artery disease, age-related … |
Toxicology CRS | 32% |
Clinical Primary efficacy | 5% |
Clinical PFS | 6.28 |
Clinical OS | 10.09 |
Clinical Result source | ClinicalTrials.gov NCT02352337 |
Clinical Data Tier / Score | A · 50 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Levoleucovorin (Levoleucovorin) Seagen, a wholly owned subsidiary …·Gastroesophageal Junction 5%·t½ 5.1 h |
|---|---|
Overview Program | Levoleucovorin |
Overview Company | Seagen, a wholly owned subsidiary of Pfizer |
Overview Modality | ANTIBODY |
Overview Target | Gastroesophageal Junction |
Overview Indication | Colorectal Neoplasms |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | target for the treatment of cancer due to its involvement in base excision repair pathway |
MoA Biomarker | biomarkers and tumor samples for archival tissues were collected from all patients |
PK/PD Half-life | 5.1 h |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pharmacokinetic |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Vitamins, Vascular Health and Disease.. Vascular health relies on the proper function of endothelial cells, which regulate vascular tone, blood fluidity, and barrier integrity. Endothelial dysfunction, often aggravated by inadequate vitamin absorption, contributes to a spectrum of clinical disorders, including cardiovascular disease, cerebrovascular disease, peripheral artery disease, age-related … |
Toxicology CRS | 32% |
Clinical Primary efficacy | 5% |
Clinical PFS | 6.28 |
Clinical OS | 10.09 |
Clinical Result source | ClinicalTrials.gov NCT02352337 |
Clinical Data Tier / Score | A · 50 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교